Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

CDC’s ACIP supports COVID-19 boosters for all adults

By Brian Buntz | November 22, 2021

CDC COVID-19The Advisory Committee on Immunization Practices (ACIP) at the CDC voted unanimously to allow all fully vaccinated adults to receive a COVID-19 booster at least six months after receiving a primary series.

All 11 members of the panel also voted on Nov. 19 to recommend boosters for adults 50 and older.

Last week, FDA authorized the mRNA vaccines from Pfizer-BioNTech (NYSE:PFE/NSDQ:BNTX) and Moderna (NSDQ:MRNA) boosters for all adults at least six months after completion of a primary series.

Previously, government authorities had recommended boosters for people 65 and older, those who are moderately to severely immunocompromised, and those at high risk of exposure in occupational or residential settings.

Several states aimed to sidestep the federal government’s booster requirements by allowing all fully adults who received an mRNA-based COVID-19 vaccine to obtain a booster, provided at least six months had elapsed before receiving the second vaccine dose.

Guidance is more precise for those who received the single-dose Janssen COVID-19 vaccine. All Janssen vaccine recipients may receive a second dose at least two months after receiving a dose of that vaccine.

ACIP recently recommended a primary vaccination series for children between the ages of 5 and 11.

The American Medical Association applauded the news. In a statement, President Dr. Gerald E. Harmon said that the AMA believes “the FDA’s authorization and the ACIP’s recommendations in support of booster doses for all adults will help provide continued protection against COVID-19 as we head into the winter months.”

While praising the move to open up booster eligibility, some physicians criticized the guidance for not encouraging all adults who received mRNA vaccines to receive boosters.

“I don’t get it, based on data from Israel and The Lancet, I don’t understand the ‘should/may’ split,” said Dr. Peter Hotez, dean for the National School of Tropical Medicine at Baylor University, over Twitter. Interpreting the federal guidance as implying that eligible adults 50 or older should obtain a booster while those 18 and older may obtain a dose “just confuses,” he added. “Everyone over 18 should get the booster. Otherwise, we won’t get back to normal.”


Filed Under: Infectious Disease
Tagged With: ACIP, Advisory Committee on Immunization Practices, BioNTech, covid-19, COVID-19 booster, COVID-19 vaccine, COVID-19 vaccines, Moderna, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer shares positive top-line data from Phase 3 Study of pneumococcal vaccine
Vaccine
The most common monkeypox vaccine side effects
FDA logo
FDA grants emergency use authorization to Jynneos monkeypox vaccine to support ‘dose sparing’
JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50